Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: Relation to the MDR phenotype and effects of reversing agents

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 672-676

  Cayre, Anne ^a   Moins, Nicole ^a   Finat Duclos, Françoise ^a   Maublant, Jean ^a   Verrelle, Pierre ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

3H daunomycin; 99mTc sestamibi; Multidrug resistance phenotype; Multidrug resistance reversing agents

Indexed keywords

DAUNORUBICIN DERIVATIVE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; 2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; DIAGNOSTIC AGENT; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRIAZINE DERIVATIVE; TRITIUM; VALSPODAR; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; CELL CULTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; PIPERIDINES; RADIOPHARMACEUTICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TECHNETIUM TC 99M SESTAMIBI; TRIAZINES; TRITIUM; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032588566     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137-171.
2. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-920.
3. Baggetto L. Non P-glycoprotein novel proteins involved in human cancer multidrug resistance. Bull Cancer. 1997;84:385-390.
4. Croop JM, Gros P, Housmann DE. Genetics of multidrug resistance. J Clin Invest. 1988;81:1303-1309.
5. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-1972.
6. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990;42:155-199.
7. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Cancer. 1993;72:3502-3514.
8. Sonneveld P, Wiemer E. Inhibitors of multidrug resistance. Curr Opin Oncol. 1997;9:543-548.
9. 99mTc-sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear Medicine Annual. New York, NY: Raven Press, Ltd.; 1994:181-234.
10. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977-984.
11. Piwnica-Worms D, Rao VV, Kronauge JF, Croop JM. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 1995;34:12210-12220.
12. Cayre A, Moins N, Finat-Duclos F, Verrelle P, Maublant J. Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitro. Effects of MDR reversing agents. J Nucl Med. 1997;38:1674-1677.
13. 3H-daunomycin and MDR reversing agents. Anticancer Drugs. 1996;7:833-837.
14. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Genet. 1985;11:117-126.
15. Chevillard S, Viehl PH, Validire P, et al. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia. 1997;11:1095-1106.
16. Maublant J, Gachon P, Moins N. Hexakis (2-methoxyisobutylisonitrile) technetium-99m- and thallium-201 chloride: uptake and release in cultured myocardials cells. J Nucl Med. 1988;29:48-54.
17. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta. 1973;323:466-483.
18. Merlin JL, Marchal S, Ramacci C, Lucas C, Parraire M, Poullain MG. Effect of the modality of exposure on the action of S9788 on the modulation of multidrug resistance of human tumor cell lines [in French]. Bull Cancer. 1994;81:906-909.
19. Bosch I, Crankshaw CL, Piwnica-Worms D, Croop JM. Characterization of functional assays of multidrug resistance P-glycoprotein transport activity. Leukemia. 1997;11:1131-1137.
20. 99mTc -sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun. 1995;16:253-257.
21. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med. 1994;35:510-515.
22. Cordobes MD, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med. 1996;37:286-289.
23. Hill BT, van der Graaf WTA, Hosking LK, de Vries EGE, Mulder NH, Whelan RDH. Evaluation of S9788 as a modulator of drug resistance against human tumor sublines expressing differing resistance mechanism in vitro. Int J Cancer. 1993;55:330-337.
24. Huet S, Chapet C, Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer. 1993;10:1377-1383.
25. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82:1107-1112.
26. Schwaller MA, Adenier A, Moreau F, Berlion M, Dunn T, Bizzari JP. Mechanism of uncoupling of S9788, a novel multidrug-resistance modulator, on rat liver mitochondria [abstract]. Clin Exp Metastasis. 1992;10:104.
27. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 1990;82: 1826-1838.
28. Roepe PD. The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim Biophys Acta. 1995;1241:385-406.
29. Maublant J. Scintigraphic imaging of breast tumors. Eur J Radiol. 1997;24:2-10.
30. Del Vecchio S, Carmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997;24:150-159.
31. Del Vecchio S, Carmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med. 1997;38:1348-1351.
32. Moretti JL, Azaloux H, Boisseron D, Kouyoumdjian JC, Vilcoq J. Primary breast cancer imaging with technetium-99m-sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med. 1996;23:980-986.
33. Kostakoglu L, Elahi N, Kïratlï P, et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med. 1997;38:1003-1008.
34. Barrand MA, Bagrij T, Neo SY. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol. 1997;28:639-645.
35. Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science. 1988;241:694-697.
36. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313-4320.
37. Moretti JL, Duran-Cordobes M, de Beco V, et al. Glutathione modulation of sestamibi-Tc-99m (MIBI) uptake in human cell lines overexpressing multidrug resistance related protein (MRP) [abstract). Eur J Nucl Med. 1997;24:904.
38. Kabasakal L, Özker K, Hayward M, et al. Technetium-99m-sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med. 1996;23:568-570.
39. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia. 1997;11:1067-1072.